Sign In
Buy OYST
$11.17
+0 (+0%)
At Close: Mar 29, 2023
Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)
04:01pm, Tuesday, 01'st Dec 2020
Planned enrollment of the first patient in the OLYMPIA Phase 2 study in 1H 2021 Planned enrollment of the first patient in the OLYMPIA Phase 2 study in 1H 2021
Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference
09:00am, Wednesday, 25'th Nov 2020
PRINCETON, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of f
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q3 2020 Results - Earnings Call Transcript
09:57pm, Saturday, 07'th Nov 2020
Oyster Point Pharma, Inc. (OYST) CEO Jeffrey Nau on Q3 2020 Results - Earnings Call Transcript
Oyster Point Pharma to Report Third Quarter 2020 Financial Results on November 5, 2020
04:01pm, Thursday, 29'th Oct 2020
Conference Call and Webcast Scheduled for November 5, 2020, 4:30 pm ET Conference Call and Webcast Scheduled for November 5, 2020, 4:30 pm ET
OC Public Libraries to Bring Internet to Low-Access Communities
08:18pm, Friday, 09'th Oct 2020
SANTA ANA, Calif. (CNS)—The Orange County Public Library system announced on Oct. 9 it is launching a WiFi ...
NFL 2020 predictions: can anyone stop Patrick Mahomes and the Chiefs?
08:00am, Thursday, 10'th Sep 2020
The NFL kicks off on Thursday. Is this the start of a Kansas City dynasty? Will Tom Brady thrive in Florida? And will Covid-19 end the season prematurely?
Chief Commercial Officer John Snisarenko Just Bought 133% More Shares In Oyster Point Pharma, Inc. (NASDAQ:OYST)
02:33pm, Monday, 17'th Aug 2020
Investors who take an interest in Oyster Point Pharma, Inc. (NASDAQ:OYST) should definitely note that the Chief...
Do Institutions Own Oyster Point Pharma, Inc. (NASDAQ:OYST) Shares?
05:02pm, Tuesday, 11'th Aug 2020
If you want to know who really controls Oyster Point Pharma, Inc. (NASDAQ:OYST), then you'll have to look at the...
We're Not Very Worried About Oyster Point Pharma's (NASDAQ:OYST) Cash Burn Rate
05:01pm, Tuesday, 11'th Aug 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Oyster Point Pharma (NASDAQ:OYST) Rating Increased to Buy at Zacks Investment Research
01:54am, Tuesday, 11'th Aug 2020
Oyster Point Pharma (NASDAQ:OYST) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Saturday, Zacks.com reports. The brokerage prese
State Street Corp Raises Holdings in Oyster Point Pharma (NASDAQ:OYST)
10:58pm, Sunday, 09'th Aug 2020
State Street Corp increased its position in shares of Oyster Point Pharma (NASDAQ:OYST) by 122.6% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor o
Analysts' Top Healthcare Picks: Global Blood Therapeutics (GBT), Oyster Point Pharma (OYST) - Markets
11:50pm, Wednesday, 05'th Aug 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Global Blood
Oyster Point Pharma Reports Second Quarter 2020 Financial Results and Recent Business Highlights
11:00am, Wednesday, 05'th Aug 2020
* OC-01 New Drug Application (NDA) Submission to U.S. Food and Drug Administration (FDA) for Signs and Symptoms of Dry Eye Disease (DED) Planned for Q4 2020 * Cash and Cash Equivalents of $226.7 mi
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
Oyster Point Pharma to Report Second Quarter 2020 Financial Results on August 5, 2020
08:01pm, Friday, 31'st Jul 2020
Conference Call and Webcast Scheduled for August 5, 2020, 8:30 am ETPRINCETON, N.J., July 31, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical comp
